Table 3.

Advances in clinical trials of anticancer drugs based on NPs have occurred over the past few decades

Posted	Identifiers	NPs-interventions	Conditions	Phase
2005	NCT00244933	Genistein + Gemcitabine	Breast Cancer	II
2005	NCT00256334	Resveratrol	Colon Cancer	I
2006	NCT00376948	Genistein + Gemcitabine + Erlotinib	Pancreatic Cancer	II
2008	NCT00764036	Artesunate	Metastatic Breast Cancer	I
2010	NCT01042938	Curcumin C3 Complex	Breast Cancer	II
2010	NCT01126879	Genistein	Prostate Cancer	II
2011	NCT01333917	Curcumin C3	Colorectal Cancer	I
2011	NCT01490996	Curcumin + FOLFOX	Colonic Cancer	I/II
2011	NCT01489813	Genistein	Bladder Cancer	II
2012	NCT01628471	Genistein + Decitabine	Non Small Cell Lung Cancer	I/II
2013	NCT01985763	Genistein + FOLFOX/FOLFOX-Avastin	Colorectal Cancer	I/II
2015	NCT02633098	Artesunate	Colorectal Cancer	II
2015	NCT02499861	Genistein + Decitabine	Solid Tumors, Leukemia	I/II
2016	NCT02714608	Ginsenoside H dripping pills	Non Small Cell Lung Cancer	II
2016	NCT02769962	Nanoparticle Camptothecin + Olaparib	Lung, Bladder, and Prostate Cancer	I/II
2018	NCT03769766	Curcumin	Prostate Cancer	III
2019	NCT03980509	Curcumin	Breast Cancer	I
2020	NCT04401059	Elemene + EGFR-TKIs	Non Small Cell Lung Cancer	IV
2020	NCT04444921	Paclitaxel + Carboplatin + Nivolumab	Anal Cancer	III
2020	NCT04251533	Nab-paclitaxel + Alpelisib	Triple Negative Breast Cancer	III
2021	NCT05035147	Albumin-bound paclitaxel	Pancreatic Cancer	IV
2021	NCT04921527	Paclitaxel + Chiauranib	Ovarian Cancer	III
2022	NCT05456022	Quercetin	Oral Cancer	II
2023	NCT05844670	Vincristine	Pediatric Cancer	IV
2023	NCT05747313	Vincristine + Chidamide	Triple Negative Breast Cancer	I/II
2023	NCT06143553	Paclitaxel Polymeric Micelles	Metastatic Breast Cancer	III
2024	NCT06355037	Quercetin + Dasatinib	Triple Negative Breast Cancer	II